Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 22.68 -0.79% -0.18
YMAB closed down 0.79 percent on Thursday, February 21, 2019, on 23 percent of normal volume.

Earnings due: Feb 26

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical YMAB trend table...

Date Alert Name Type % Chg
Feb 21 Bearish Engulfing Bearish 0.00%
Feb 21 Upper Bollinger Band Walk Strength 0.00%
Feb 21 Upper Bollinger Band Touch Strength 0.00%
Feb 20 Shooting Star Candlestick Bearish -0.79%
Feb 20 Lizard Bearish Bearish Day Trade Setup -0.79%
Feb 20 Doji - Bearish? Reversal -0.79%
Feb 20 Stochastic Reached Overbought Strength -0.79%
Feb 20 Earnings Movers Other -0.79%
Feb 20 Above Upper BB Strength -0.79%
Feb 20 Overbought Stochastic Strength -0.79%

Older signals for YMAB ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Biopharmaceutical Cancer Cancer Treatment Brain Tumor Neuroblastoma Glioma Diffuse Intrinsic Pontine Glioma Refractory
Is YMAB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.0
52 Week Low 15.17
Average Volume 73,205
200-Day Moving Average 0.0
50-Day Moving Average 20.9256
20-Day Moving Average 21.2665
10-Day Moving Average 21.799
Average True Range 1.4972
ADX 15.36
+DI 20.4179
-DI 15.6234
Chandelier Exit (Long, 3 ATRs ) 19.8284
Chandelier Exit (Short, 3 ATRs ) 23.0916
Upper Bollinger Band 22.9997
Lower Bollinger Band 19.5333
Percent B (%b) 0.91
BandWidth 16.299814
MACD Line 0.3347
MACD Signal Line 0.0912
MACD Histogram 0.2435
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.84
Resistance 3 (R3) 24.85 24.15 24.48
Resistance 2 (R2) 24.15 23.60 24.14 24.36
Resistance 1 (R1) 23.41 23.26 23.06 23.40 24.24
Pivot Point 22.71 22.71 22.53 22.70 22.71
Support 1 (S1) 21.97 22.16 21.62 21.96 21.12
Support 2 (S2) 21.27 21.82 21.26 21.00
Support 3 (S3) 20.53 21.27 20.88
Support 4 (S4) 20.52